ATE265043T1 - Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease - Google Patents

Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease

Info

Publication number
ATE265043T1
ATE265043T1 AT00987612T AT00987612T ATE265043T1 AT E265043 T1 ATE265043 T1 AT E265043T1 AT 00987612 T AT00987612 T AT 00987612T AT 00987612 T AT00987612 T AT 00987612T AT E265043 T1 ATE265043 T1 AT E265043T1
Authority
AT
Austria
Prior art keywords
hiv
coding sequence
hiv protease
protease
recombinant
Prior art date
Application number
AT00987612T
Other languages
English (en)
Inventor
Stefano Menzo
Massimo Clementi
Original Assignee
Biostrands S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostrands S R L filed Critical Biostrands S R L
Application granted granted Critical
Publication of ATE265043T1 publication Critical patent/ATE265043T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT00987612T 1999-12-15 2000-12-14 Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease ATE265043T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99830776A EP1109019A1 (de) 1999-12-15 1999-12-15 Verfahren zur Ermittlung der Empfindlichkeit von HIV-Varianten gegen Hemmstoffe der HIV-Protease
PCT/IT2000/000518 WO2001044508A2 (en) 1999-12-15 2000-12-14 Method to evaluate the sensitivity of hiv variants to drugs able to inhibit the hiv protease

Publications (1)

Publication Number Publication Date
ATE265043T1 true ATE265043T1 (de) 2004-05-15

Family

ID=8243712

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00987612T ATE265043T1 (de) 1999-12-15 2000-12-14 Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease

Country Status (9)

Country Link
US (1) US20030175690A1 (de)
EP (2) EP1109019A1 (de)
AT (1) ATE265043T1 (de)
AU (1) AU2395101A (de)
BR (1) BR0016409A (de)
CA (1) CA2393620A1 (de)
DE (1) DE60010127D1 (de)
RU (1) RU2002118706A (de)
WO (1) WO2001044508A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009374D0 (en) * 2000-04-14 2000-05-31 Glaxo Group Ltd Phenotyping assay and reagents therefor
WO2004002511A1 (ja) * 2002-06-28 2004-01-08 Fuso Pharmaceutical Industries, Ltd. 抗ｈｉｖ剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571666A (en) * 1988-10-28 1996-11-05 Oklahoma Medical Research Foundation Thiazine dyes used to inactivate HIV in biological fluids
AU717755B2 (en) * 1996-01-26 2000-03-30 Virco Bvba Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains

Also Published As

Publication number Publication date
EP1242818B1 (de) 2004-04-21
US20030175690A1 (en) 2003-09-18
BR0016409A (pt) 2002-08-20
CA2393620A1 (en) 2001-06-21
EP1109019A1 (de) 2001-06-20
RU2002118706A (ru) 2004-02-27
WO2001044508A3 (en) 2002-01-03
AU2395101A (en) 2001-06-25
EP1242818A2 (de) 2002-09-25
DE60010127D1 (de) 2004-05-27
WO2001044508A2 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
FR2808803B1 (fr) Cellules es modifiees et gene specifique de cellules es
Bushman et al. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA.
DE69635864D1 (de) Rekombinante rna-replikase von hepatitis-c-virus
ATE456677T1 (de) Hiv-1 detektion mittels nukleinsäureamplifizierung
Semaan et al. Cytotoxic effects during knock out of multiple porcine endogenous retrovirus (PERV) sequences in the pig genome by zinc finger nucleases (ZFN)
DE69840743D1 (de) Nukleinsäure-primer und -sonden zur detektion von hiv-1 und hiv-2
DE50214416D1 (de) Vermehrung von viren in zellkultur
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
ATE480643T1 (de) Homogener nachweis von analyten
DK1725573T3 (da) Fremgangsmåde og materialer ved anvendelse af signalsonder
DE602004020999D1 (de) Materialien und verfahren zum einfangen von krankheitserregern und zur abtrennung von aurintricarbonsäure aus einer probe
DE69833660D1 (de) Nukleinsäuresonden zur detektion von candida-spezies
DE50010710D1 (de) Verfahren zur bestimmung von substanzen mittels der evaneszenzfeldmethode
DE60010127D1 (de) Verfahren zur ermittlung der empfindlichkeit von hiv-varianten gegen hemmstoffe der hiv-protease
DE60129809D1 (de) In vitro evolution von nukleinsäuren und kodierten polypeptiden
ES2054769T3 (es) Polipeptidos hiv-2 recombinantes.
Bona et al. Development of a human immunodeficiency virus vector-based, single-cycle assay for evaluation of anti-integrase compounds
ATE197071T1 (de) Nachweis von nukleinsäure-amplifikation mittels fluoreszenz-polarisation
ATE305612T1 (de) Reporterverbindungen und verfahren zur auffindung von hochspezifische proteaseaktivität
ATE348190T1 (de) Verfahren zum nachweis von protein- proteininteraktionen in membranen
DE60121547D1 (de) Electrochemisches verfahren zum nachweis von nukleinsäuren
Müller et al. Cell biological aspects of HIV-1 infection: effect of the anti-HIV-1 agent avarol
EA199800438A1 (ru) Способ и набор для количественного определения и обнаружения микроорганизмов
TW200502399A (en) Recombinant virus and use thereof and method of detecting an analyte in a sample and kit thereof
DE60040874D1 (de) Amplifizierung von hiv-1 sequenzen zur detektion ven einhergehen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties